Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 2, 2006, Pages 343-350

  Schmidt, C ^a   Wittig, B M ^b   Moser, C ^c   Zeitz, M ^b   Stallmach, A ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Evangelisches Krankenhaus Zweibrucken   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; KETOCONAZOLE; MESALAZINE; MESNA; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; ERYTHEMA NODOSUM; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REMISSION; SEPTICEMIA; URINARY TRACT INFECTION;

ADULT; AZATHIOPRINE; CROHN DISEASE; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PROSPECTIVE STUDIES; REMISSION INDUCTION; STEROIDS; TREATMENT OUTCOME;

EID: 33745638741     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02988.x     Document Type: Article

References (28)

1. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1994; 86: 249-66.
3. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104: 1293-301.
4. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 370-4.
5. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
6. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000067.
7. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
8. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl JMed 1997; 337: 1029-35.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
10. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098.
11. Glück T, Reng M, Linde HJ, Müller-Ladner U, Schölmerich J. Anti-TNF therapy and Listeria monocygotenes infection - report of two cases. Arthritis Rheum 2002; 46: 2255.
12. Richmond R, McMillan T, Luqmani R. Optimisation of cyclophosphamide therapy in systemic vasculitis. Clin Pharmacokinet 1998; 34: 79.
13. Donadio JVJ, Glassock RJ. Immunosuppressive drug therapy in lupus nepritis. Am J Kidney Dis 1993; 21: 239.
14. Colvin OM. An overview of cyclophosphamide development and clinical application. Curr Pharm Des 1999; 5: 555.
15. Ahmed A, Hombal S. Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol 1984; 11: 1115.
16. Lacki JK, Schochat T, Sobieska M. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol 1994; 53: 76.
17. Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 2003; 52: 377-82.
18. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001; 68: 287-97.
19. Adler G, Reinshagen M. Extraintestinal manifestations. Z Gastroenterol 2003; 41: 54-61.
20. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 313: 614-9.
21. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide. Ann Rheum Dis 1983; 42: 368-73.
22. Baker GL, Kahl LE, Zee BE. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Am J Med 1989; 83: 1-9.
23. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomarosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-10.
24. Martin F, Lauwerys B, Lefebre C, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254-7.
25. Paton NI. Infections in systemic lupus erythematosus patients. Ann Acad Med Singapore 1997; 26: 694-700.
26. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15: 528-34.
27. Guillevin L, Cordier J, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
28. Koldingsnes W, Gran J, Omidal R, Husby G. Wegener's granulomatosis: long term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol 1998; 37: 659-64.